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Abstract
Background: Bronchial thermoplasty (BT) is a bronchoscopic procedure that improves asthma control by reducing
excess airway smooth muscle. Treated patients have been followed out to 5 years to evaluate long-term safety of
this procedure.
Methods: Patients enrolled in the Asthma Intervention Research Trial were on inhaled corticosteroids ≥200 μg
beclomethasone or equivalent + long-acting-beta2-agonists and demonstrated worsening of asthma on long-
acting-b2-agonist withdrawal. Following initial evaluation at 1 year, subjects were invited to participate in a 4 year
safety study. Adverse events (AEs) and spirometry data were used to assess long-term safety out to 5 years post-BT.
Results: 45 of 52 treated and 24 of 49 control group subjects participated in long-term follow-up of 5 years and
3 years respectively. The rate of respiratory adverse events (AEs/subject) was stable in years 2 to 5 following BT (1.2,
1.3, 1.2, and 1.1, respectively,). There was no increase in hospitalizations or emergency room visits for respiratory
symptoms in Years 2, 3, 4, and 5 compared to Year 1. The FVC and FEV1 values showed no deterioration over the
5 year period in the BT group. Similar results were obtained for the Control group.
Conclusions: The absence of clinical complications (based on AE reporting) and the maintenance of stable lung
function (no deterioration of FVC and FEV1) over a 5-year period post-BT in this group of patients with moderate
to severe asthma support the long-term safety of the procedure out to 5 years.
Background
Asthma continues to be a major health concern world-
wide, with over 23 million people in the United States
who suffer with this disease [1]. Approximately 5-10% of
these patients are characterized as having severe persis-
tent asthma based on continued presence of asthma
symptoms despite treatment with current state-of-the-
art medications [2]. Poorly controlled asthma impacts
the patient’s quality of life, increases healthcare utiliza-
tion, and imposes both a social as well as an economic
burden [3-8].
The recent approval of the Alair® Bronchial Thermo-
plasty System for delivering bronchial thermoplasty (BT)
provides an additional option for managing patients
with severe asthma. BT provides therapeutic benefit by
reducing the amount of excess smooth muscle in the
airways, with the resultant effect of reducing broncho-
constriction in response to asthma triggers. Results from
the Asthma Intervention Research (AIR) Trial, the first
randomized clinical trial of BT which compared BT plus
standard-of-care therapy (inhaled corticosteroids (ICS)
and long-acting-b2-agonists (LABA)) to standard-of-care
alone, demonstrated that the mean rate of mild exacer-
bations, as compared with baseline, was reduced in the
BT group but was unchanged in the control group.
Furthermore at 12 months, when subjects were on ICS
alone, there were significantly greater improvements in
the BT group than in the control group in the morning
peak expiratory flow, scores on the AQLQ and ACQ,
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the percentage of symptom-free days and symptom
scores, while fewer puffs of rescue medication were
required [9]. Two additional randomized controlled
trials, the Research in Severe Asthma (RISA) Trial [10],
and the sham-controlled Asthma Intervention Research
2 (AIR2) Trial [11], have provided additional support for
the effectiveness of BT. The safety of BT over the post-
treatment period out to one year was established in all 3
randomized clinical studies. Because BT is a novel treat-
ment that alters the amount of airway smooth muscle,
and asthma is a chronic disease that is associated with
structural changes in the airway wall, it is important to
know whether this treatment is associated with any
longer term adverse outcomes. Longer-term safety data
out to 5 years are available for a small cohort of BT
treated subjects from the first clinical study of patients
with mild to moderate asthma [12,13]. We now describe
the safety profile of BT out to 5 years post-treatment
from patients with moderate to severe asthma from the
AIR Trial [9].
Methods
Study subjects
All patients completing the 12-month follow-up evalua-
tions in the AIR Trial (BT group: standard-of-care +
BT; Control group: standard-of-care) were invited to
participate in a 5 year post-treatment extension study to
evaluate longer-term safety under a new protocol
(NCT00448812). The exclusion criteria for participation
in the extension study were: participation in another
clinical trial involving respiratory intervention, or new
diagnosis of psychiatric disorder which in the judgment
of the investigator could interfere with provision of
informed consent, completion of tests, therapy, or
follow-up.
The key inclusion criteria to establish eligibility of
patients to participate in the original AIR Trial were:
18-65 year old ambulatory adults; stable asthma (no
unscheduled visits or change to medications within
6 weeks prior to randomization); requiring inhaled corti-
costeroids (ICS): at least 200 μg beclomethasone or
equivalent per day, and long-acting b2-agonist (LABA):
at least 100 μg salmeterol or equivalent per day; demon-
stration of worsening of asthma after 2-week LABA
withdrawal; pre-bronchodilator FEV1 ≥ 60% and ≤ 85%
predicted; methacholine PC20 < 8 mg/ml; and, non-
smoker x 1 yr; if former smoker, less than 10 pack-year
history. The key exclusion criteria were: history of ≥ 3
lower respiratory tract infections per year (requiring
antibiotics); and, requirement of > 4 puffs/day of a
short-acting b2-agonist, excluding for exercise. The pro-
tocol for the longer-term extension study was approved
by the respective Institutional Review Boards/Ethics
Committees at each participating institution prior to
obtaining a signed informed consent from the study
participants.
Study procedures
Subjects in the BT group were evaluated annually; at
Year 2, Year 3, Year 4, and Year 5 after their last treat-
ment bronchoscopy. Subjects in the Control group were
evaluated at Year 2 and Year 3 and then exited from the
study. Year 1 data are provided for matched pairs in
both the BT and Control groups comprising those sub-
jects that enrolled in the longer-term follow-up.
Annual evaluations included a physical examination,
pre- and post-bronchodilator spirometry, static lung
volumes, diffusing capacity, chest x-ray (PA and Lateral),
methacholine PC20 (out to Year 3 only), as well as active
solicitation of information on any adverse events, emer-
gency room visits and hospitalizations for asthma symp-
toms, oral corticosteroid pulses for worsening asthma
symptoms, and any changes in maintenance asthma
medications. Maintenance asthma medication use, oral
corticosteroid use, adverse events, emergency room vis-
its and hospitalizations were verified through medical
record review for about 80% of the subjects whose pri-
mary care was under the supervision of the investigator
at their respective institution. X-ray observations
reported by radiologists at each site were collectively
reviewed by an independent pulmonologist to assess
clinical relevance of the observations if any.
During Year 1, adverse events were solicited during 12
office visits and 9 telephone contacts over the course of
the year, as well as a review of the medical chart. During
the longer-term follow-up, adverse events were actively
solicited from the subject during the annual evaluation
and through a review of the medical chart for the prior
year for subjects managed at the investigator’s institute.
The recording of adverse events in Year 1 (AIR Trial)
differed from the subsequent years (AIR Extension
Study) in that in Year 1, multiple symptoms associated
with an adverse event were collected as individual
adverse events; while in the subsequent years, an adverse
event with multiple symptoms was counted as a single
adverse event e.g., multiple respiratory symptoms asso-
ciated with worsening of asthma were considered as a
single event called “asthma (multiple symptoms)”
adverse event.
Statistical Analyses
Demographics
Group means were compared using Student’s t-test.
Hospitalizations and Emergency Room Visits for respira-
tory symptoms: The respective number of subjects com-
pleting each annual follow-up visit was used to calculate
the proportion of subjects with hospitalizations or emer-
gency room visits for respiratory symptoms in each year.
Thomson et al. BMC Pulmonary Medicine 2011, 11:8
http://www.biomedcentral.com/1471-2466/11/8
Page 2 of 9
Fisher’s Exact test was used to compare proportion of
subjects with respiratory hospitalizations and emergency
room visits in the BT and Control groups during Years
1, 2 and 3. Trends in the percent of subjects with hospi-
talizations or emergency room visits for respiratory
symptoms across Years 1 to 5 were investigated using a
repeated measures logistic regression (generalized esti-
mating equation), modeling the percent of subjects
reporting the event. Maintenance medications ICS dose:
Change from Baseline to each follow-up year in ICS
dose was analyzed with a Signed Rank test.
Results
Demographics and Clinical Characteristics
Forty five (45) of the 52 subjects in the BT group (87%),
and 24 of the 49 subjects in the Control group (49%)
who completed the Year 1 evaluation opted to partici-
pate in the extension study. The 7 subjects in the BT
group and 25 subjects in the Control group who
declined to participate in the long-term follow-up did so
for personal reasons, and not due to mortality. The
numbers of subjects enrolling for the longer-term fol-
low-up and those completing scheduled annual evalua-
tions are summarized in Table 1.
The baseline demographic information and clinical
characteristics (at time of entry into the AIR Trial) for
subjects participating in the extension study are pro-
vided in Table 2. The groups were well matched with
no statistically significant differences between them for
any given parameter.
Safety
Adverse Events
There were no incidences of pneumothorax, intubation,
mechanical ventilation, cardiac arrhythmias, or death as
a result of BT treatment over the 5 year follow-up.
Respiratory adverse events reported during the course
of the 5 year follow-up are summarized in Table 3. Dur-
ing Year 1, the rate of respiratory adverse events in both
the BT and Control groups was higher as a result of the
method of recording the adverse events whereby multi-
ple symptoms associated with an adverse event were
recorded as separate adverse events. In subsequent years
(Year 2 to Year 5), an adverse event with multiple symp-
toms was recorded as a single adverse event. The rate of
respiratory adverse events in the BT group (AEs/subject)
remained stable in years 2 to 5 following BT. A repeated
measures analysis for the “asthma (multiple symptoms)”
adverse events which reflects worsening asthma control
showed no deterioration over time from Year 2 to Year
5 (p = 0.47). During Year 2 and Year 3, when data for
the Control group was collected, the respiratory adverse
event rate between the BT and Control groups was not
significantly different.
Respiratory adverse events occurring at a by-subject
incidence rate of ≥3.0% in any of the years are given in
Table 4. For the majority of respiratory adverse events,
the incidence rates were stable during each year from
Year 2 to Year 5 in the BT group, and from Year 2 and
Year 3 in the Control group. The respiratory adverse
events were typical of asthma. One subject in the BT
group who had undergone the procedure was diagnosed
with a lung abscess in the previously treated left upper
lobe at 14 months (Year 2), and was resolved with surgi-
cal resection. The subject had undergone BT unevent-
fully and had completed the 12 month follow-up with
normal spirometric values and good asthma control
(Post-BD FEV1 at baseline was 2.27L, and at 12 months
was 2.33L). Histological examination of the dissected
lung did not reveal an obstruction or any other poten-
tially contributory abnormality in the airways as a result
of the treatment. The abscess was considered secondary
to an infection. At the time of exit from the study at
5 years, the post-BD FEV1 for this subject was 1.78L
compared to baseline value of 2.27L.
Healthcare Utilization Events
During Year 1 and Year 2, more subjects in the BT
group required hospitalizations for respiratory symp-
toms than the Control group, but these differences were
not significant. There was one hospitalization for
respiratory symptoms in the Control group in Year 3.
Over the course of the 5 year post-BT follow-up, the
number of hospitalizations, and the proportion of sub-
jects experiencing hospitalizations for respiratory symp-
toms did not get worse compared to Year 1 after BT
(Table 5) (p = 0.16; repeated measures analysis for pro-
portion of subjects). Similarly, the number of emergency
room (ER) visits for respiratory symptoms and the pro-
portion of subjects experiencing ER visits for respiratory
symptoms remained comparable and did not get worse
Table 1 Number of Subjects Evaluated Annually out to
5 Years
Subjects
Completing 1
Year Follow-up
in AIR Trial
Subjects
Enrolling for
Longer-Term
Follow-up
Subjects Completing
Follow-up
Year
2
Year
3
Year
4
Year
5
BT 52 45 41a 41b 43 42c
Control 49 24 23d 21e - -
a: 4 subjects missed visit.
b: 2 subjects missed visit; 1 subject withdrew consent; 1 subject Lost-to-
Follow-up.
c: 1 subject missed visit.
d: 1 subject missed visit.
e: 2 subjects withdrew consent after completing Year 2 evaluation, and 1
subject withdrew consent mid-Year 3.
Control group subjects exited from study after completing Year 3 evaluation.
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in Years 2, 3, 4, and 5 compared to Year 1 (Table 5)
(p = 0.55; repeated measures analysis). The number of
ER visits for respiratory symptoms in the Control group
in Years 2 and 3 were comparable to the BT group (p =
0.41 and p = 1.00, respectively; Fisher’s Exact test).
Oral Corticosteroid Use for Asthma Symptoms
The frequency of OCS usage for worsening of asthma symp-
toms is shown in Table 6. Neither the rate of OCS usage nor
the proportion of subjects requiring OCS pulses showed any
worsening over the 5 year period in the BT group. OCS
Table 2 Baseline Demographics and Clinical Characteristics
BT (n = 45) Control (n = 24)
Age (yrs) 40.0 ± 11.2 40.8 ± 12.1
Gender Male 19 (42%) Male 9 (38%)
Female 26 (58%) Female 15 (63%)
Race White 41 (91%) White 22 (92%)
Black 3 (7%) Black 2 (8%)
Asian 1 (2%) Asian 0 (0%)
Height (cm) 166.1 ± 9.6 164.8 ± 7.7
Weight (kg) 76.3 ± 23.3 77.7 ± 16.9
Inhaled Corticosteroid Dose (μg)a 1305 ± 880 1141 ± 1053
LABA Dose (μg)b 109 ± 34 100 ± 15
Symptom-Free Days (%) 33.3 ± 34.3 46.1 ± 41.0
Asthma Control Questionnaire (ACQ) Score 1.3 ± 0.6 1.2 ± 0.7
Asthma Quality of Life Questionnaire (AQLQ) Score 5.6 ± 0.9 5.6 ± 0.9
Rescue Medication Use (No. of puffs/7days) 10.6 ± 14.7 5.5 ± 10.4
Emergency Room Visits for Respiratory Symptoms in prior 12 monthsc
No. Events (No. Subjects)
3 (3) 0 (0)
Hospitalizations for Respiratory Symptoms in prior 12 monthsc
No. Events (No. Subjects)
3 (3) 2 (2)
Lung Function Measures
Morning PEF (L/min) 368.4 ± 99.7 394.1 ± 111.7
Pre-Bronchodilator FEV1 (% predicted) 72.5 ± 10.9 74.9 ± 8.9
Post-Bronchodilator FEV1 (% predicted) 84.4 ± 13.8 86.1 ± 9.5
Diffusion Capacity (mL/min/mm Hg) 15.7 ± 10.7 15.9 ± 11.7
Total Lung Capacity (L) 6.0 ± 1.2 5.9 ± 1.3
Residual Volume (L) 2.1 ± 0.7 2.0 ± 0.7
Methacholine PC20 (mg/ml) 0.25 0.28
Geometric mean (range) (0.2, 0.4) (0.1, 0.6)
Definition of abbreviations: BT = Bronchial Thermoplasty; LABA = Long-Acting b2-Agonist;
PEF = Peak Expiratory Flow Rate; FEV1 = Forced Expiratory Volume in 1 second.
Values are mean ± SD.
a: Beclomethasone or equivalent.
b: Salmeterol or equivalent.
c: Patient reported.
BT versus Control: All parameters, Not significant (Student’s t-test of the mean).
Table 3 Summary of Respiratory Adverse Events
Year 1 Year 2 Year 3 Year 4 Year 5
Number of subjects BT 45a 45 43 43 42
Control 24a 24 21 – b – b
Number of subjects reporting (Percent of subjects) BT 38 (84%) 24 (53%) 24 (56%) 23 (53%) 22 (52%)
Control 18 (75%) 13 (54%) 12 (57%) – –
Events per subject BT 4.5 1.2 1.3 1.2 1.1
Control 3.1 1.2 1.3 – –
a: Year 1 data only for subjects who enrolled for longer-term follow-up.
b: Control group subjects exited from Study after Year 3 evaluations.
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usage for asthma symptomswas comparable between the BT
and Control groups during Years 1, 2 and 3.
Maintenance Asthma Medication Use
During the review of maintenance asthma medications
at each annual visit, the medication dosages for a
number of subjects had been adjusted to reflect their
current level of asthma control. Compared to their base-
line pre-BT usage, over the course of the 5 years, an
average of 57% of BT subjects reported a decrease in
their LABA use, 40% of subjects reported no change in
Table 4 Subjects with Respiratory Adverse Events (All events reported at ≥3.0% in any year)
Year 1a Year 2 Year 3 Year 4b Year 5b
Adverse Event BT
(n = 45)
Control
(n = 24)
BT
(n = 45)
Control
(n = 24)
BT
(n = 43)
Control
(n = 21)
BT
(n = 43)
BT
(n = 42)
Dyspnea 19 (42.2%) 12 (50.0%) 4 (8.9%) 3 (12.5%) 4 (9.3%) 3 (14.3%) 4 (9.3%) 4 (9.5%)
Cough 17 (37.8%) 7 (29.2%) 4 (8.9%) 1 (4.2%) 2 (4.7%) 3 (14.3%) 3 (7.0%) 2 (4.8%)
Wheeze 14 (31.1%) 4 (16.7%) 2 (4.4%) 1 (4.2%) 3 (7.0%) 1 (4.8%) 3 (7.0%) 2 (4.8%)
Nasal congestion 13 (28.9%) 5 (20.8%) 2 (4.4%) 0 0 0 0 1 (2.4%)
Upper Respiratory Tract Infection 10 (22.2%) 2 (8.3%) 11 (24.4%) 4 (16.7%) 8 (18.6%) 4 (19.1%) 8 (18.6%) 4 (9.5%)
Productive cough 9 (20.0%) 5 (20.8%) 2 (4.4%) 1 (4.2%) 2 (4.7%) 0 0 1 (2.4%)
Chest discomfort 8 (17.8%) 3 (12.5%) 2 (4.4%) 2 (8.3%) 3 (7.0%) 1 (4.8%) 1 (2.3%) 2 (4.8%)
Nasopharyngitis 6 (13.3%) 0 1 (2.2%) 0 0 0 1 (2.3%) 1 (2.4%)
Nocturnal Dyspnea 6 (13.3%) 2 (8.3%) 0 0 0 0 0 0
Respiratory Tract Infectionc 5 (11.1%) 5 (20.8%) 3 (6.7%) 2 (8.3%) 5 (11.6%) 1 (4.8%) 5 (11.6%) 4 (9.5%)
Pharyngolaryngeal pain 5 (11.1%) 3 (12.5%) 0 0 0 0 0 0
Respiratory Tract congestion 4 (8.9%) 2 (8.3%) 0 0 0 0 0 0
Discolored sputum 4 (8.9%) 0 3 (6.7%) 0 0 0 0 0
Rhinitis 2 (4.4%) 0 0 0 1 (2.3%) 0 0 2 (4.8%)
Bronchitisd 1 (2.2%) 0 1 (2.2%) 1 (4.2%) 1 (2.3%) 2 (9.5%) 1 (2.3%) 1 (2.4%)
Pharyngitis 1 (2.2%) 1 (4.2%) 0 0 0 0 0 0
Pleuritic Pain 1 (2.2%) 1 (4.2%) 0 0 0 0 0 0
Rhinorrhea 1 (2.2%) 1 (4.2%) 0 0 1 (2.3%) 0 0 0
Asthma (multiple symptoms)e 0 0 4 (8.9%) 2 (8.3%) 7 (16.3%) 1 (4.8%) 7 (16.3%) 6 (14.3%)
Sinusitis 0 0 1 (2.2%) 1 (4.2%) 2 (4.7%) 0 2 (4.7%) 2 (4.8%)
Nasal polyps 0 0 1 (2.2%) 0 0 0 2 (4.7%) 0
Pneumonia 0 0 0 0 1 (2.3%) 1 (4.8%) 0 0
a: Year 1 data only for subjects who enrolled for longer-term follow-up. Adverse events solicited from patient during multiple office visits in Year 1. In
subsequent years, adverse events solicited only at annual follow-up visit.
b: Control group subjects exited from Study after Year 3 evaluations.
c: Includes adverse events reported as “Respiratory Tract Infection” and “Lower Respiratory Tract Infection”.
d: Includes adverse events reported as “Bronchitis” and “Tracheobronchitis”.
e: Asthma - In Year 1, all symptoms were collected as individual adverse events; in subsequent years, multiple symptoms of asthma exacerbation were
considered as a single adverse event.
Table 5 Summary of Healthcare Utilization Events
Hospitalizations
Percent of Subjects [95% CI]
(Number of Events)
Emergency Room Visits
Percent of Subjects [95% CI]
(Number of Events)
Total Number of Subjects BT Control p-valueb BT Control p-valueb
Year 1 BT = 45
Control = 24
6.7% [0.0, 14.0]
(3)
0 0.55 4.4% [0.0, 10.5]
(2)
0 0.54
Year 2 BT = 45
Control = 24
6.7% [0.0, 14.0]
(3)
0 0.55 6.7% [0.0, 14.0]
(3)
12.5% [0.0, 25.7]
(3)
0.41
Year 3 BT = 43
Control = 21
2.3% [0.0, 6.8]
(3)
4.8% [0.0, 13.9]
(1)
1.00 4.7% [0.0, 10.9]
(3)
4.8% [0.0, 13.9]
(3)
1.00
Year 4a BT = 43
Control = 0
2.3% [0.0, 6.8]
(1)
– 9.3% [0.6, 18.0]
(6)
–
Year 5a BT = 42
Control = 0
2.4% [0.0, 7.0]
(1)
– 4.8% [0.0, 11.2]
(2)
–
a: Control group subjects exited from Study after Year 3 evaluations.
b: p-value from Fisher’s Exact test.
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their LABA use, and 3% reported an increase in their
LABA use. In the Control group, over the course of the
3 years, an average of 54% of Control subjects reported
a decrease in their LABA use, 43% of subjects reported
no change in their LABA use, and 3% reported an
increase in their LABA use. In the same period an aver-
age of 49% of subjects in the BT group and 47% of sub-
jects in the Control group were no longer taking LABA
as controller medication.
The mean reduction from baseline in ICS dose for BT
subjects was 182 μg/day (p = 0.09), 135 μg/day (p =
0.32), 150 μg/day (p = 0.25), 151 μg/day (p = 0.23), and
194 μg/day (p = 0.16) at Years 1, 2, 3, 4, and 5 respec-
tively (p-values from a Signed Rank test). At Year 3, the
mean reduction in the ICS daily dose in the Control
group was 112 μg/day. The reduction in ICS was not
significantly different between the BT group and the
Control group at years 2 and 3 (p = 0.93 for Year 2, and
p = 0.92 for Year 3), years when data were available for
both the BT and Control groups. At 3 years the propor-
tion of subjects in the BT group with changes from
baseline in their maintenance ICS dose was 27% with a
decrease, 56% with no change, and 17% with an
increase. The corresponding numbers for the Control
group were 29%, 52% and 19% respectively.
Review of Serial (Annual) Chest X-rays
18 of the 45 BT subjects (40%), and 9 of the 24 Control
subjects (37%) had finding(s) noted on chest x-rays.
Findings ranged from air trapping, pleural thickening,
increased density/consolidation, hyperinflation, nodules/
granuloma, increased vascular markings, and bronchial
wall thickening. None of the findings noted in either
group were clinically significant structural changes. The
findings noted were either pre-existing, minor and tran-
sient, or consistent with acute inter-current illnesses
that typically occur in patients with moderate and severe
asthma.
Pulmonary Function Tests
Pulmonary function tests were performed when subjects
were taking only ICS as their maintenance asthma medi-
cation (either after a 2 week withdrawal of LABAs for
subjects that were on ICS+LABA or for subjects on just
ICS). The mean post-bronchodilator FEV1 and FVC
values over time are presented graphically in Figure 1,
respectively. Both measures of lung function (FEV1 and
FVC) remained stable and showed no deterioration over
the 5 year period post-BT.
Similarly, total lung capacity and residual volumes
remained stable out to 5 years in the BT group. There
were small improvements over baseline in Diffusion
Capacity in both the BT and Control groups over the
course of the study.
There was an improvement over baseline in the metha-
choline PC20 doubling in the BT group compared to the
Control group in each year out to Year 3. The differences
between groups were statistically significant in Year 2
and Year 3, but not in Year 1 (methacholine PC20 dou-
blings BT versus Control: Year 1: 1.53 ± 2.29 vs 1.00 ±
2.46, p = 0.378; Year 2: 1.21 ± 2.99 vs -0.47 ± 2.31, p =
0.024; Year 3: 1.31 ± 2.96 vs -0.44 ± 2.27, p = 0.025).
Discussion
The recently approved Alair System for bronchial ther-
moplasty provides a new treatment option for patients
with severe asthma that remain symptomatic despite
taking inhaled corticosteroids and long-acting-b2-
agonists, the current standard-of-care medications.
Three randomized clinical trials in patients with differ-
ing severity of asthma have demonstrated the safety of
this device-based treatment out to one year [9-11]. In
the AIR Trial, at 12 months post-treatment, while
patients were on ICS alone, these benefits included sig-
nificantly greater improvements in the BT group than in
the Control group in mild exacerbation rates, morning
peak expiratory flow, scores on the AQLQ and ACQ,
the percentage of symptom-free days and symptom
scores, while fewer puffs of rescue medication were
required [9]. Each of these studies has also reported on
the short-term (treatment period) and long-term (out to
12 months) adverse event profile associated with the
bronchial thermoplasty. The reported increase in
respiratory adverse events in the short-term represented
the further aggravation of the worsening of asthma
symptoms that is associated with bronchoscopy in
patients with asthma [14]. During the long-term post-
treatment period out to 12 months, fewer subjects in
the BT group reported respiratory adverse events [9-11].
Data are now presented for the safety of this treatment
over a 5 year period.
Table 6 Use of Oral Corticosteroid Pulses for Asthma
Symptoms
Oral Corticosteroid Pulses:
Events/Subject/Year
(Percent of Subjects)
Total Number of Subjects BT Control
Year 1a BT = 45
Control = 24
0.60 (24.5%)c 0.42 (20.8%)c
Year 2 BT = 45
Control = 24
0.49 (24.5%) 0.54 (33.3%)
Year 3 BT = 43
Control = 21
0.33 (25.6%) 0.52 (23.8%)
Year 4b BT = 43
Control = 0
0.63 (27.9%) –
Year 5b BT = 42
Control = 0
0.62 (30.9%) –
a: Year 1 data only for subjects who enrolled for longer-term follow-up.
b: Control group subjects exited from Study after Year 3 evaluations.
c: Includes adverse events reported as “Asthma”, “Exacerbations of asthma”,
“Wheeze”, “Dyspnea”, and “Respiratory infection”.
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BT is a novel treatment that alters the amount of air-
way smooth muscle, and asthma is chronic disease that is
associated with structural changes in the airway wall, it
was important to know whether this treatment is asso-
ciated with any longer term adverse outcomes. The parti-
cipation of patients originally enrolled in the AIR Trial in
this additional 4 year follow-up study provides data to
support the longer-term safety of BT out to at least
5 years. The absence of serious events indicates that the
integrity of the airways is not compromised over the long
term as a result of BT treatment. This is supported by
the observation of no deterioration of baseline FEV1 or
FVC over this period, and the ability of the airways to
respond to bronchodilator administration. While the rate
of decline in lung function can vary in asthma, with some
subjects demonstrating equivalent declines to those with-
out airways disease, and others suffer an accelerated
decline [15-17], it is reassuring that following BT, there
was no significant loss of lung function over a 5 year per-
iod. The rate of occurrence of respiratory related adverse
events remained low and stable between Year 2 and Year
5 (1.1 to 1.3 events/subject/year) and comparable to the
Control group for Year 2 and Year 3 (1.2 and 1.3 events/
subject/year, respectively). The frequency and method of
collecting adverse events in this study was different in
Year 1 compared to the other 4 years, resulting in a
higher rate of respiratory adverse events in both the BT
and Control groups in Year 1. During Year 1, the solicita-
tion of adverse events was more frequent (12 office visits
and 9 telephone contacts) compared to subsequent years
when adverse events were solicited once a year and could
be subject to recall bias. Also important is the fact that
during Year 1, multiple symptoms for a given adverse
event were recorded as individual adverse events as com-
pared to the subsequent years when multiple related
symptoms were recorded as a single event. Because of
these methodological issues, comparisons of adverse
event rates within each group for Year 1 and subsequent
years are not appropriate. The lower rates of respiratory
adverse events in Years 2 to 5 compared to Year 1 may
reflect some underreporting as a result of recall bias at
the yearly solicitation of adverse events. Every effort was
made to carefully solicit adverse events from study sub-
jects during annual evaluations and augmented with a
thorough review of medical records at participating insti-
tutions. Review of medical charts is lacking for instances
where a subject may have been treated for adverse event(s)
at a different institution.
Figure 1 FEV1 and FVC over Time. Post-bronchodilator FEV1 and FVC over time. Data represent group mean values for each year. Note that
participation of the Control subjects in the study was terminated after Year 3 evaluation.
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Measures such as ER Visits and hospitalizations for
respiratory symptoms are generally considered to be
important measures of safety, especially if an interven-
tion results in an increase in the rate of one or more of
these events. Consistent with the low rate of respiratory
adverse events is the stable incidence of healthcare utili-
zation events (hospitalizations and emergency room vis-
its for respiratory symptoms). There was no worsening
of the proportion of subjects in the BT group experien-
cing hospitalizations or ER visits for respiratory symp-
toms beyond Year 1 out to 5 years. The rates of ER
visits and the proportion of subjects with ER visits in
the Control group were comparable to the BT group
during Years 1, 2, and 3. Longer-term safety of BT is
supported further by our findings of no deterioration in
measurements of static and dynamic lung volumes or
diffusing capacity over the 5 years post-treatment. In
addition airway responsiveness to methacholine
remained stable in the BT group out to the last mea-
surement performed at year 3 post-treatment. Stable
lung function measures in this group of patients with
moderate to severe asthma support the previously
reported conclusion based on lung function measures
[12,13] and high resolution CT [13] that BT-treated air-
ways do not develop late scarring that could result in
narrowing of the airways [12].
Although x-rays are not sensitive enough for the pur-
pose of demonstrating structural abnormalities, a review
of the serial x-rays obtained annually did not reveal any
clinically significant findings. While the use of high
resolution computed tomography (HCRT) would have
been more informative, it was not performed in this
study.
Bronchial hyperresponsiveness to methacholine
improved in the thermoplasty group in years 2 and 3,
but not in year 1. This is an interesting result in favour
of a long-term efficacy of the procedure. However, the
lack of follow-up of the control group on years 4 and 5
and the observational nature of the data limits the rele-
vance of this finding.
There are several limitations to the study. Firstly, not
all patients enrolled in the Asthma Intervention
Research Trial participated in long-term follow-up,
although none of the reasons for non-participation was
due to mortality. Secondly, the follow-up period was
longer in patients who received BT (at 5 years) com-
pared to the Control group (3 years). Subjects who had
been randomized to the Control group in the predeces-
sor AIR Trial may have opted to pursue other treatment
options, and for those that agreed to the longer-term
follow up, it was deemed to be unethical [18] to require
them to withhold other alternative treatment options
(including new experimental treatments) for a period of
5 years in order to avoid confounding of data.
Nevertheless a high proportion of patients who received
BT (86%) participated in long-term follow-up, which
provides support for the generalizability of the safety
data. Thirdly, the solicitation of adverse events on a
yearly basis has the potential of under reporting due to
recall bias. However, the occurrence of major events
such as severe exacerbations (steroid pulses for asthma
symptoms), emergency room visits, and hospitalizations
is less frequent and less likely to be forgotten and there-
fore not reported. Medical charts were reviewed to ver-
ify steroid pulses prescribed for asthma symptoms
(severe exacerbations) and reported adverse events or to
identify adverse events that may not have been reported
by the subject, unless the subject had presented at a dif-
ferent medical facility for an adverse event during that
year. Finally, the study was not blinded and this may
add bias to the eliciting of adverse events. Despite these
limitations, over the 5 year follow-up of BT treated sub-
jects, the absence of unexpected respiratory adverse
events, no increases in hospitalizations or emergency
room visits for respiratory symptoms, and maintenance
of stable lung function demonstrated safety of BT out to
5 years.
Conclusions
This report provides long-term safety data on BT in
patients in whom BT was performed by trained opera-
tors, and patients were carefully observed especially in
the first year. The absence of clinical complications
based on adverse event reporting, healthcare utilization
events, and the maintenance of stable lung function (no
deterioration of FEV1) over a 5-year period post-BT in
patients with moderate to severe asthma suggest long-
term safety of the procedure out to 5 years.
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